<?xml version="1.0" encoding="UTF-8"?>
<results title="funders">
 <result pre="activity [295,297,298]. Fomivirsen, developed by Isis Pharmaceuticals in collaboration with" exact="Novartis" post="Opthalmics, was in 1998 the first oligonucleotide-based therapy to"/>
 <result pre="an oxindole compound with anti-HCMV activity identified by screening a" exact="Roche" post="kinase inhibitor library, also inhibited IE2 and pp28 protein"/>
 <result pre="inhibited IE2 and pp28 protein levels [356]. Screening of the" exact="GlaxoSmithKline" post="kinase inhibitor set identified SB-734117, a furazan benzimidazole compound,"/>
 <result pre="of the manuscript. Funding This research was funded by the" exact="Medical Research Council," post="grant number MR/P022146/1, to M.M.N. Conflicts of Interest The"/>
 <result pre="and has anti-human cytomegalovirus activityAntivir. Res.2017144212610.1016/j.antiviral.2017.05.00428501424 357.KhanA.S.MurrayM.J.HoC.M.K.ZuercherW.J.ReevesM.B.StrangB.L.High-throughput screening of a" exact="GlaxoSmithKline" post="protein kinase inhibitor set identifies an inhibitor of human"/>
</results>
